To investigate SH3YL1 as a potential biomarker for kidney injury, particularly in the context of cisplatin-induced nephrotoxicity, quantitative ELISA was conducted on plasma and urine samples from bladder cancer patients. The gene discussed is SH3YL1; the disease is urinary bladder carcinoma.